Xcout Intel
Cinclus Pharma competitors & alternatives
The 12 closest competitors and alternatives to Cinclus Pharma among pharmaceuticals companies — ranked by similarity to what Cinclus Pharma actually does, not by market-cap band.
Subscribe to see Cinclus Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Cinclus Pharma
Cinclus Pharma is a clinical-stage pharmaceutical company based in Stockholm, Sweden. The firm is focused on achieving a paradigm shift in the treatment of acid-related diseases by developing and advancing targeted drug candidates like GERD treatments.
Cinclus Pharma at a glance
Cinclus Pharma is a pharmaceuticals company headquartered in Sweden. Its most recent funding round, Series B, closed in March 2020. Xcout tracks 7 named people at Cinclus Pharma, including Lennart Hansson (Chairman of the Board, Co-founder).
Cinclus Pharma leadership
- Lennart HanssonChairman of the Board, Co-founder
- Anders LundströmNon-executive Director
- David ArmstrongNon-executive Director
- Fredrik JohanssonNon-executive Director
- Helena LevanderNon-executive Director
- Torbjörn KoivistoNon-executive Director
1 more named person on record for Cinclus Pharma, with roles, board committees and tenure — see the full roster →
Cinclus Pharma funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | Undisclosed | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Cinclus Pharma competitors
Ranked by semantic similarity — how close each company is to Cinclus Pharma by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Similar pharmaceuticals company
Melius Pharma is a Swedish clinical-stage pharmaceutical company that develops new treatments for severe diseases with high unmet clinical needs. Its primary focus is the development of its lead candidate, ME-015, as a treatment for chronic cough in patients with idiopathic pulmonary fibrosis (IPF).
Similar pharmaceuticals company
Egetis Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of treatments for serious, rare diseases with high unmet medical needs. Operating internationally, the public company has its headquarters in Stockholm, Sweden, alongside a growing presence in the United States. Its clinical pipeline targets specialized therapeutic indications to improve patient outcomes.
Similar pharmaceuticals company
Pila Pharma AB is a clinical-stage biotechnology company that develops oral TRPV1 antagonists as potential treatments for obesity and diabetes. The company serves patients suffering from these metabolic conditions by advancing innovative, non-injectable drug candidates through preclinical and clinical research.
Similar pharmaceuticals company
Purpose Pharma International AB is a European pharmaceutical company headquartered in Stockholm, Sweden. The firm is dedicated to giving people with rare diseases a better quality of life.
Similar pharmaceuticals company
Ferring Pharmaceuticals is a specialty biopharmaceutical company that develops and delivers treatments in reproductive medicine, maternal health, gastroenterology, urology, and uro-oncology. The company focuses on helping people build families, supporting maternal and infant health, and providing therapeutic solutions for various medical conditions worldwide.
Similar pharmaceuticals company
RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegoprazan, designed to treat gastroesophageal reflux disease (GERD), is currently undergoing Phase 1 clinical trials in the United States. Grapiprant is in Phase II development in the U.S. and Phase I in China for pain management; it is also being investigated in Phase I studies in both the U.S. and China for its potential in cancer therapy. Beyond human medicines, RaQualia Pharma develops a range of veterinary products. These include grapiprant for managing osteoarthritis in dogs, a ghrelin receptor agonist aimed at addressing cancer-related anorexia/cachexia syndrome and constipation stemming from spinal cord injury, and ELURA, a medication for combating weight loss in cats suffering from chronic kidney disease. The company's extensive R&D pipeline also covers various other therapeutic areas. This includes a TRPM8 blocker for neuropathic pain, a motilin receptor agonist targeting gastrointestinal motility disorders such as gastroparesis, functional dyspepsia, and post-operative ileus, and a potassium-competitive acid blocker for GERD, which has successfully concluded Phase 1 clinical trials. Further early-stage developments encompass a 5-HT4 partial agonist for gastroparesis, functional dyspepsia, and chronic constipation; a 5-HT2B antagonist for irritable bowel syndrome with diarrhea; EP4 antagonists for canine pain management and, in separate Phase I trials, for cancer and general pain indications; a serotonin 5-HT2A and dopamine D2 receptor blocker for schizophrenia; a Cyclooxygenase-2 inhibitor (Phase I for pain); a CB2 agonist; a selective sodium channel blocker; a P2X7 receptor antagonist (Phase I for neuropathic pain); and a retinoic acid receptor alpha agonist. To further its research and development initiatives, RaQualia maintains strategic partnerships with Interprotein Corporation, ASKA Pharmaceutical Co., Ltd., and Epigeneron, Inc.
Similar pharmaceuticals company
Saniona AB is a clinical-stage biopharmaceutical company that discovers and develops treatments for neurological disorders and rare diseases. The company utilizes its proprietary ion channel drug discovery engine and proprietary molecule library to advance a pipeline of potential new medicines targeting conditions such as epilepsy and hypothalamic obesity.
Pharmaceuticals & Biotechnology
Promore Pharma is a Stockholm-based biopharmaceutical company listed on the Nasdaq First North exchange. The company specializes in developing therapeutic peptides and first-in-category treatments, focusing particularly on scar management.
Similar pharmaceuticals company
SFJ Pharmaceuticals is a privately held pharmaceutical development and investment company that helps advance drug candidates through clinical development and regulatory approval. It serves biotechnology and pharmaceutical partners by providing development funding, operational expertise, and global clinical-trial support.
Similar pharmaceuticals company
RDD Pharma Ltd. is a biopharmaceutical company focused on the discovery and development of therapeutic products for gastrointestinal and anorectal diseases. Headquartered in Israel with locations in Tel Aviv and Ofakim, the company specializes in targeted treatments.
Similar pharmaceuticals company
Orexo AB is a pharmaceutical company that specializes in developing innovative drug delivery technologies, notably its powder-based AmorphOX platform. The company advances proprietary and partnered pharmaceutical products, including treatments, vaccines, and nasal delivery formulations, serving patients and healthcare partners globally.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Cinclus Pharma and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Cinclus Pharmaand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →